New auto-enrolment amendments in effect
The secondary legislation that sets out the detail on how workplace pension reform works was subject to two phases of amendment in the Automatic Enrolment (Miscellaneous Amendment) Regulations 2013.
The first phase (covering the definition of pay reference periods, retention periods, opt-out notices and the test scheme standard for defined-benefit schemes) applied from 1 November 2013.
The second phase has applied from 1 April 2014. With effect from that date, the deadlines for employers to provide information to individuals on their opt-in rights, information to individuals on their joining rights, postponement notices, the auto-enrolment joining window and deadlines for registration are extended from one month to six weeks…
Click on the link below to read the rest of the Wragge & Co briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.